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Additional key phrases: cystatin C; creatinine; creatinine clearance. renal failure Determination of serum creatinine and creatinine clearance are commonly used for the estimation of glomerular filtration rate (GFR) despite well-known theoretical and practical limitations. In search of more suitable markers of GFR, several low-molecular-weight proteins (Prmicroglobulin, alpha I microglobulin, cystatin C, ribonuclease, retinol-binding protein) have been investigated for their usefulness in detecting reduced GFR especially within the socalled 'creatinine-blind' range. I Chrornogranin A is one of a group of acidic proteins co-stored and co-released with catecholamines from the adrenal medulla. Serum chromogranin A is a useful adjunct for the diagnosis of neuroendocrine tumours but its usefulness is limited by retention in patients with renal dysfunction.i-' In a previous study, we showed retention of chromogranin A immunoreactive species with declining renal function in patients who had received a renal transplant." The aim of the present study is to evaluate whether serum chromogranin A could be used as an endogenous marker of G FR by comparing its serum concentration with other markers of GFR (serum creatinine and cystatin e concentrations and creatinine clearance) in patients with varying degrees of renal dysfunction.
MATERIALS AND METHODS

Patients and samples
The leftover serum samples, stored at -80"e, of 85 consecutive patients aged 27-66 years who had been referred for routine estimation of creatinine clearance were used for the study.
Methods
Serum chromogranin A was determined by enzyme-linked immunosorbent assay (ELISA;
Correspondence: 0 A Mojiminiyi. E-mail: segunadete.yahoo.corn DAKO, Glostrup, Denmark). The assay utilizes a rabbit polyclonal antibody (A430) raised against a 23 kDa C-terminal fragment of chromogranin A purified from the urine of a patient with carcinoid syndrome. Serum cystatin e was determined by a latex-particle-enhanced immunoturbidimetric assay (DAKO). The method was adapted for use on the Hitachi 911 automated analyser (Boehringer Mannheim, Mannheim, Germany) which was also used to determine serum and urine creatinine. A liver profile (i.e., serum bilirubin, total protein and albumin levels, and activities of alanine aminotransferase, alkaline phosphatase and 'l'-glutamyl transpeptidase) was also performed to exclude liver disease, which is known to cause elevation of serum chromogranin A. 2 None of the patients studied had biochemical evidence of liver disease.
Statistical methods
Serum chromogranin A was not normally distributed and results are expressed as the median and inter-quartile (25th-75th percentile) range. Other results are expressed as means with standard deviation. Spearman rank correlation coefficient (rs) and regression were used to study the association between variables. Values of P < 0·05 were considered to be statistically significant.
RESULTS AND DISCUSSION
The intra-assay coefficient of variation for the chromogranin A and cystatin e assays were 6·2 and 4·8%, respectively; the inter-assay coefficients of variation were 3·6 and 2,8%, respectively, at serum chromogranin A concentration of 30·5 U/L and cystatin e concentration of 3·21 mg/L, Analytical recovery was assessed by adding different concentrations of chromogranin A or cystatin e standard solution to a serum pool of known concentration. The percentage recovery was calculated as the percentage ratio between the measured and added concentrations of chromogranin A or cystatin C. The analytical recoveries for the chromogranin A and cystatin C assays were 86-110% and 93-106%, respectively.
The range of creatinine clearance, cystatin C and chromogranin A in the patients were 2·4-138 ml.rmin, 0,85-6,8 mg/L and 3·0--528 U/L, respectively. Serum chromogranin A showed the same classical curvilinear relationship shown by serum creatinine and cystatin C with creatinine clearance (Fig. 1) . Serum chromogranin A showed good correlation with serum creatinine [rs = 0·74 (confidence interval (CI) 0·6 to 0,9)], creatinine clearance [rs= -0·85 (CI-O'92 to -0·73)] and cystatin C [rs=0'84 (CI 0·70 to 0,91)].
In 35 patients with normal creatinine clearance (80--139 ml.jrnin) the median (inter-quartile range) serum chromogranin A was 6·6 (4'2-13) U/L and the mean (SD) serum creatinine, creatinine clearance and cystatin C were 74·1 (19'1) Ilmol/L, 112·5 (13'1) ml.jmin and 1·19 (0'17) mg/L, respectively. In 15 patients with creatinine clearance between 50--80mL/min, the median (inter-quartile range) serum chromogranin A was 16·5 (14,0--22,0) U/L and the mean (SD) serum creatinine, creatinine clearance and cystatin C were 106·6 (39'6) Ilmol/L, 62·5 (7'2) mL/min and 1·72 (0'54) mg/L, respectively. In the latter group of patients 10 of the 15 patients had normal ( < 30 U /L) serum chromogranin A concentrations and this compares with 4 of the IS patients with normal « 1·5 mg/L) serum cystatin C and 12 of the 15 patients with normal serum creatinine « 110 Ilmol/L in women and < 120llmol/L in men).
Chromogranin A is mainly catabolized in the kidney by glomerular filtration followed by tubular absorption and metabolism. This study confirms a previous report which suggested that retention of chromogranin A in patients with renal transplant and declining renal function is due, in part, to reduced GFR. 4 Other factors which may contribute to elevated serum chromogranin A in patients with renal dysfunction include hypertension as well as the secondary hyperparathyroidism which develops early in patients with reduced GFR. The diagnostic sensitivity and specificity of elevated serum chromogranin A (> 30 U/L) in detecting creatinine clearance <80mL/min are 67 and 100%, respectively. These are better than the values for serum creatinine (sensitivity 59% and specificity 72%) and compare to the sensitivity and specificity of serum cystatin C of 94 and 100%, respectively. Compared with cystatin C, the . lower sensrtivrty obtained with serum chromogranin A could be due to wider inter-individual variability resulting from the presence of multiple immunoreactive species? and various physiological and pathological factors known to affect serum chromogranin A concentration.
In conclusion, serum chromogranin A could be used as a marker ofGFR but it is not as good as cystatin C. In the absence of neuroendocrine tumour and liver disease, an elevated serum chromogranin A is indicative of renal dysfunction and this could be useful in monitoring renal function in some patients (such as patients with a renal transplant). The retention of chromogranin A in patients with renal dysfunction leads to serum concentrations comparable to those seen in patients with neuroendocrine tumoursv'. Since chromogranin A is a precursor of metabolically active peptides such as pancreastatin (which inhibits insulin secretion) and chromostatin,' further studies are required to investigate the endocrine and metabolic consequences of its retention in patients with renal failure.
